NASDAQ:ZURA Zura Bio (ZURA) Stock Price, News & Analysis $2.05 +0.04 (+1.99%) Closing price 08/25/2025 04:00 PM EasternExtended Trading$2.08 +0.03 (+1.46%) As of 04:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Zura Bio Stock (NASDAQ:ZURA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Zura Bio alerts:Sign Up Key Stats Today's Range$1.95▼$2.0750-Day Range$1.05▼$2.0552-Week Range$0.97▼$5.07Volume263,637 shsAverage Volume391,867 shsMarket Capitalization$133.29 millionP/E RatioN/ADividend YieldN/APrice Target$14.00Consensus RatingBuy Company Overview Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada. Read More Zura Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreZURA MarketRank™: Zura Bio scored higher than 70% of companies evaluated by MarketBeat, and ranked 296th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingZura Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageZura Bio has only been the subject of 3 research reports in the past 90 days.Read more about Zura Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Zura Bio are expected to decrease in the coming year, from ($0.65) to ($0.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zura Bio is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zura Bio is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZura Bio has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Zura Bio's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.38% of the float of Zura Bio has been sold short.Short Interest Ratio / Days to CoverZura Bio has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Zura Bio has recently decreased by 8.77%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZura Bio does not currently pay a dividend.Dividend GrowthZura Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.38% of the float of Zura Bio has been sold short.Short Interest Ratio / Days to CoverZura Bio has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Zura Bio has recently decreased by 8.77%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.43 News SentimentZura Bio has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Zura Bio this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for ZURA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Zura Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Zura Bio insiders have not sold or bought any company stock.Percentage Held by Insiders22.10% of the stock of Zura Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.14% of the stock of Zura Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Zura Bio's insider trading history. Receive ZURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zura Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ZURA Stock News HeadlinesFY2025 EPS Estimates for Zura Bio Lifted by HC WainwrightAugust 23 at 2:45 AM | americanbankingnews.comHC Wainwright Issues Pessimistic Forecast for Zura Bio (NASDAQ:ZURA) Stock PriceAugust 21, 2025 | americanbankingnews.comTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed professionals, retirees, and high-net-worth savers. But the wealthy aren’t just writing checks. They’re moving fast to protect capital and purchasing power using legal, IRS-compliant strategies. American Alternative Assets just released the Mar-A-Lago Accord, a free guide revealing how to reduce Q3 tax exposure and reposition wealth before it’s drained. | American Alternative (Ad)Zura Bio price target lowered to $2 from $3 at H.C. WainwrightAugust 19, 2025 | msn.comOppenheimer Has Lowered Expectations for Zura Bio (NASDAQ:ZURA) Stock PriceAugust 18, 2025 | americanbankingnews.comZura Bio's (ZURA) Buy Rating Reiterated at Chardan CapitalAugust 17, 2025 | americanbankingnews.comZura Bio price target lowered to $16 from $17 at OppenheimerAugust 15, 2025 | msn.comZura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate UpdatesAugust 14, 2025 | businesswire.comSee More Headlines ZURA Stock Analysis - Frequently Asked Questions How have ZURA shares performed this year? Zura Bio's stock was trading at $2.50 at the beginning of the year. Since then, ZURA stock has decreased by 18.0% and is now trading at $2.05. How were Zura Bio's earnings last quarter? Zura Bio Limited (NASDAQ:ZURA) posted its quarterly earnings data on Thursday, August, 14th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. Who are Zura Bio's major shareholders? Zura Bio's top institutional investors include JPMorgan Chase & Co. (6.81%), VR Adviser LLC (6.77%), Geode Capital Management LLC (0.60%) and Alberta Investment Management Corp (0.19%). Insiders that own company stock include Someit Sidhu, Van Amstel Arnout Ploos, Michael Howell, Kiran Nistala and Parvinder Thiara. View institutional ownership trends. How do I buy shares of Zura Bio? Shares of ZURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zura Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zura Bio investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walt Disney (DIS). Company Calendar Last Earnings8/14/2025Today8/25/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ZURA CIK1855644 WebN/A Phone858-247-0520FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Price Target for Zura Bio$14.00 High Price Target$26.00 Low Price Target$2.00 Potential Upside/Downside+582.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.39 million Net MarginsN/A Pretax MarginN/A Return on Equity-49.11% Return on Assets-40.06% Debt Debt-to-Equity RatioN/A Current Ratio8.40 Quick Ratio8.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.27 per share Price / Book0.90Miscellaneous Outstanding Shares65,020,000Free Float50,649,000Market Cap$133.29 million OptionableOptionable Beta-0.06 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:ZURA) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zura Bio Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zura Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.